Cholinesterase inhibition remains the mainstay of therapy

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)37
Number of pages1
JournalDrug Benefit Trends
Volume13
Issue number7
StatePublished - 2001

Fingerprint

Cholinesterases
Therapeutics

ASJC Scopus subject areas

  • Leadership and Management
  • Pharmaceutical Science

Cite this

Cholinesterase inhibition remains the mainstay of therapy. / Farlow, Martin.

In: Drug Benefit Trends, Vol. 13, No. 7, 2001, p. 37.

Research output: Contribution to journalArticle

@article{766e7b5f084945388eaef7e43ea8b026,
title = "Cholinesterase inhibition remains the mainstay of therapy",
author = "Martin Farlow",
year = "2001",
language = "English",
volume = "13",
pages = "37",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "7",

}

TY - JOUR

T1 - Cholinesterase inhibition remains the mainstay of therapy

AU - Farlow, Martin

PY - 2001

Y1 - 2001

UR - http://www.scopus.com/inward/record.url?scp=0034927013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034927013&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 37

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - 7

ER -